StockNews.com began coverage on shares of FibroGen (NASDAQ:FGEN – Free Report) in a research report sent to investors on Monday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.
FibroGen Price Performance
NASDAQ FGEN opened at $0.32 on Monday. FibroGen has a fifty-two week low of $0.30 and a fifty-two week high of $2.93. The business has a 50 day moving average price of $0.38 and a two-hundred day moving average price of $0.81. The stock has a market cap of $31.83 million, a PE ratio of -0.13 and a beta of 0.70.
FibroGen (NASDAQ:FGEN – Get Free Report) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.09. The firm had revenue of $50.64 million during the quarter, compared to analysts’ expectations of $33.00 million. During the same quarter last year, the company posted ($0.65) earnings per share. Sell-side analysts anticipate that FibroGen will post -0.91 EPS for the current fiscal year.
Institutional Trading of FibroGen
FibroGen Company Profile
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.
Further Reading
- Five stocks we like better than FibroGen
- Where Do I Find 52-Week Highs and Lows?
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Insider Buying Explained: What Investors Need to Know
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- 5 Top Rated Dividend Stocks to Consider
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.